DARA signs commercialization agreement with Uman Pharma for anticancer agent

Gemcitabine is indicated for first-line therapy for ovarian, breast, lung, and pancreatic cancers.

Uman is expected to file an abbreviated new drug application (ANDA) for gemcitabine with the FDA later in 2012.

The companies are working to identify future partnership opportunities for additional sterile injectable products in the oncology market.

DARA president and CEO David Drutz said the agreement with Uman for rights to commercialize the chemotherapeutic drug in the US leverages its existing cancer drug development program.

"The exclusive agreement provides DARA with an additional commercial opportunity and further establishes a platform for adding other cancer and cancer-support products through ongoing licensing efforts," Drutz added.